IP Library Granted Patent US 8,951,973
Granted Patent B2
US 8,951,973 · App. 13/060,676 · Granted Feb 10, 2015

Controlled-released peptide formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,951,973
App. No.
13/060,676
Granted
Feb 10, 2015
Kind
B2
Abstract

Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Claims (8)

1. A controlled-release pharmaceutical formulation comprising a modified bioactive agent encapsulated by a polymer selected from poly(lactide-co-glycolide), poly(lactide), poly(glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(lactide-co-glycolide-co-caprolactone), poly(glycolide-co-caprolactone), or a mixture thereof, wherein said modified bioactive agent is a peptide having the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:9.

2. The controlled-release pharmaceutical formulation according to claim 1 , wherein said polymer is poly(lactide-co-glycolide).

3. The controlled-release pharmaceutical formulation according to claim 1 or 2 , wherein said modified bioactive agent is a peptide having the amino acid sequence set forth in SEQ ID NO:2.

4. The controlled-release pharmaceutical formulation according to claim 1 or 2 , wherein said modified bioactive agent is a peptide having the amino acid sequence set forth in SEQ ID NO:3.

5. The controlled-release pharmaceutical formulation according to claim 1 or 2 , wherein said modified bioactive agent is a peptide having the amino acid sequence set forth in SEQ ID NO:4.

6. The controlled-release pharmaceutical formulation according to claim 1 or 2 , wherein said modified bioactive agent is a peptide having the amino acid sequence set forth in SEQ ID NO:6.

7. The controlled-release pharmaceutical formulation according to claim 1 or 2 , wherein said modified bioactive agent is a peptide having the amino acid sequence set forth in SEQ ID NO:7.

8. The controlled-release pharmaceutical formulation according to claim 1 or 2 , wherein said modified bioactive agent is a peptide having the amino acid sequence set forth in SEQ ID NO:9.

Assignments (5)
SECURITY INTEREST Recorded Jan 21, 2026
From: SURMODICS MD, LLC
To: BANK OF MONTREAL, AS COLLATERAL AGENT
Reel/Frame 074461/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS COATINGS, LLC
Reel/Frame 073928/0178 →
COLLABORATION AGREEMENT Recorded Aug 16, 2024
From: CORDEN PHARMA BRUSSELS, S.A.
To: SURMODICS PHARMACEUTICALS, INC.
Reel/Frame 068669/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2011
From: BURTON, KEVIN; TICE, THOMAS
To: SURMODICS PHARMACEUTICALS, INC.
Reel/Frame 026358/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2011
From: WOEHR, TORSTEN; AYOUB, MIMOUN
To: CORDEN PHARMA
Reel/Frame 026358/0845 →